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Received May 8, 2012; accepted June 8, 2012AbstractCirrhosis is associated with hyperdynamic circulation, which consists of peripheral vasodilatation and increased cardiac output. Peripheral
vasodilatation is central to hyperdynamic circulation and portal hypertension in cirrhosis. However, those mechanisms underlying hyperdynamic
circulation remain elusive, and are not fully understood. Most of the earlier research and attention have been focused on humoral factor
abnormalities. Various gut-derived or locally produced humoral factors such as nitric oxide, endotoxin, endocannabinoids, and others have been
implicated as possible mediators of hyperdynamic circulation development in cirrhosis. The associated cardiac dysfunction had been termed
“cirrhotic cardiomyopathy (CCM),” which is an entity different from that seen in alcoholic heart muscle disease. Clinically, these patients
present with sodium fluid retention, and strain often unmasks the presence of latent heart failure. No specific treatment can yet be recommended,
but caution should be used with respect to procedures that may stress the heart such as shunt implantation and liver transplantation. Ultimately,
additional research will be necessary to more accurately describe the prevalence, impact, and morbidity and survival rates for CCM, and to
identify potential treatments.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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cirrhosis eventually progress, at variable rates, to end-stage
liver failure. In addition, mortality due to hepatic failure,
variceal bleeding, and infection are common in the advanced
stages of the condition. In cirrhosis, despite hyperdynamic
circulation at rest, the cardiac response to stimuli is blunted,
a phenomenon termed cirrhotic cardiomyopathy (CCM).* Corresponding author. Dr. Ying-Ying Yang, Division of General Medicine,
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Shih-Pai Road, Taipei 112, Taiwan, ROC.
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http://dx.doi.org/10.1016/j.jcma.2012.08.015In 1953, Kowalski and Abelmann described hyperdynamic
circulation in patients with cirrhosis.1 This occurrence is
characterized by increased cardiac output, decreased periph-
eral vascular resistance, and arterial hypotension. Because of
the hyperdynamic circulation, it was initially assumed that
cardiac function must be normal. However, studies from the
late 1960s showed that ventricular contractile responsiveness
to various stimuli such as drugs and exercise was blunted,
suggesting latent cardiomyopathy.2e6 For example, in patients
with cirrhosis, Gould et al reported that exercise doubled the
left ventricular end-diastolic pressure, but did not change
cardiac output, indicating a markedly blunted cardiac
response.7 However, this and essentially all other studies of
that era focused on patients with alcoholic cirrhosis, and thus
cardiac dysfunction was presumed to reflect latent alcoholic
cardiomyopathy. Only in the last 20 years was similar
subnormal responsiveness documented in animal models ofhinese Medical Association. All rights reserved.
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many studies have been published showing abundant evidence
that humans with nonalcoholic cirrhosis also show similar
myocardial hyporesponsiveness to stimuli.2e6 Indeed, in
human nonalcoholic cirrhosis, both systolic and diastolic
ventricular dysfunction have been clearly demonstrated.2e6
Specific diagnostic criteria for CCM have recently been
formulated by an international expert consensus committee
(Table 1). The consensus definition of CCM is “chronic
cardiac dysfunction in patients with cirrhosis, characterized by
blunted contractile responsiveness to stress, and/or altered
diastolic relaxation with electrophysiological abnormalities, in
the absence of known cardiac disease.”
CCM also satisfies the general definition of diastolic heart
failure, i.e., prolonged/inadequate diastole in the presence of
preserved/normal systole (such as ejection fraction). Certainly,
diastolic dysfunction is present in patients and animal models
with cirrhosis. Numerous studies have demonstrated that
indices of diastolic filling, such as the E/A ratio [usually due to
decreased “E” (early) diastolic filling], are often abnormal in
patients with cirrhosis, even at rest.2e6 Thus in cirrhosis,
diastolic dysfunction appears to be more common than
systolic dysfunction.4e6,8 Indeed, the pioneering description of
CCM by Gould and colleagues noted above represents an
example of diastolic dysfunction.1.2. Clinical implications of CCMWith the advent of procedures which stress the cardiovas-
cular system, the clinical significance of CCM is being
increasingly appreciated by general medical practitioners. InTable 1
Definition of cirrhotic cardiomyopathy.
General definition:
Cirrhotic cardiomyopathy is defined as chronic cardiac dysfunction in patients
with cirrhosis, characterized by blunted contractile responsiveness to stress,
and/or altered diastolic relaxation with electrophysiological abnormalities,
in the absence of known cardiac disease.
Diagnostic criteria:
1. Abnormal systolic contractile responses to stress.
2. Diastolic dysfunction at rest.
3. Absence of clinically significant cardiopulmonary disease.
Systolic dysfunction (at least one of the following):
1. Blunted increase in cardiac output with exercise, volume challenge or
pharmacological stimuli.
2. Resting LVEF <55%
Diastolic dysfunction (at least one of the following):
1. E/A ratio (age corrected) <1.0
2. Prolonged deceleration time (>200 ms)
3. Prolonged isovolumic relaxation time (>80 ms)
Supportive criteria:
1. Electrophysiological abnormalities including the following:
 Abnormal chronotropic response to stress.
 Electromechanical uncoupling/dyssynchrony.
 Prolonged QTc interval.
2. Heart chamber alterations: enlarged LA, increased LVWT.
3. Increased pro-BNP and BNP.
4. Increased troponin I.
BNP ¼ brain natriuretic peptide; LVEF ¼ left ventricular ejection fraction;
LVWT ¼ left ventricula wall thickness.particular, the widespread use of liver transplantation has
highlighted the limitation of cardiac reserve. Up to 56% of
patients, most of them with no previous history of cardiac
disease, develop clinical or radiographic evidence of pulmonary
edema during their post-transplantation hospital course.9
Cardiac-related causes account for 7e15% of all deaths after
transplantation.10,11 Moreover, other surgical stresses including
transjugular (transjugular intrahepatic portosystemic shunt or
TIPS) and surgical portosystemic shunting procedures have also
been reported to precipitate overt heart failure.3e6,12 For
example, in a recent large randomized trial comparing TIPS
with large volume paracentesis, 12% of the TIPS group devel-
oped overt heart failure, whereas none of the paracentesis group
suffered a similar heart-related problem.13
Cazzaniga et al recently examined the predictive risk
factors for death after TIPS insertion.14 Multivariate analysis
showed that only the degree of diastolic dysfunction (E/A
ratio) at day 28 after the procedure (but not baseline E/A) was
a significant predictor of 1-year mortality. Thus, the diastolic
response to the increased preload caused by the TIPS is
crucial, as emphasized in our accompanying editorial.15
Moreover, another recent study suggests that insufficient
ventricular contractile reserve contributes to the pathogenesis
of hepatorenal syndrome (HRS). Ruiz-del-Arbol et al studied
23 patients with cirrhosis who were admitted with spontaneous
bacterial peritonitis (SBP).16 SBP is a known risk factor for the
development of acute HRS. Despite antibiotic treatment and
infection resolution, 8 patients developed HRS, whereas 15
had unimpaired renal function. The major difference between
these two groups was the cardiac response: the HRS group had
a lower baseline cardiac output than the non-HRS group.
Moreover, cardiac output actually declined after infection
resolution in the HRS group, whereas it remained unchanged
in the non-HRS group. A longitudinal study by these authors
found that amongst a cohort of 66 patients with severe
cirrhosis, 27 who went on to develop HRS had lower cardiac
output and elevated serum markers of hyperdynamic
circulation.17
The prototypical inflammatory phenotype of cardiac
dysfunction is septic cardiodepression, mediated largely
through cytokines such as tumor necrosis factor-a (TNF-a).18
Indeed, it has been suggested that CCM is indistinguishable
from septic cardiodepression. However, there are several
notable differences between the two syndromes; the most
significant among them being the relative electrophysiological
changes. The various phenomena found in patients with
cirrhosis such as QT prolongation and electromechanical
dyssynchrony (abnormally wide dispersion of the normally
tightly regulated time interval between the onset of the elec-
trical QRS complex and mechanical systole) have not been
observed in septic cardiodepression.19,20 Moreover, correction
of sepsis rapidly reverses the cardiodepression, whereas liver
transplantation takes several months to reverse the functional
contractile responses in CCM.
The medical community still has its skeptics regarding the
existence of CCM, because overt heart failure is rare in
patients with cirrhosis. However there are two important
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failure. First, the vasodilated peripheral circulation unloads
the heart and, in effect, “auto-treats” the circulation. Second,
we have found a partially compensatory decrease in some
negatively inotropic regulatory mechanisms such as Gi
protein.21,22 Both cumulative phenomenological and mech-
anistic evidences has markedly reduced the linegering
concerns of the unconvinced about the existence of CCM in
cirrhosis.
2. Pathophysiology of CCM2.1. b-Adrenergic receptorCardiac contractility is regulated by several systems
including the sympathetic nervous system. The b-adrenergic
receptor (b-AR) when occupied by norepinephrine leads to
cyclic adenosine monophosphate (cAMP) generation, which
then stimulates the protein kinase A-catalyzed (PKA cata-
lyzed) phosphorylation of sarcoplasmic reticulum (SR)
proteins [calcium-releasing receptors called ryanodine recep-
tors (RyR)] that ultimately result in calcium transients which
induce actinemyosin cross-bridging and thus cell con-
traction.23e25 PKA also phosphorylates several other key
proteins to enhance contractility/relaxation, including phos-
pholamban (which increases Ca2þ reuptake by SR), troponin I
on the thin (actin) filament, and myosin-binding protein-C on
the thick (myosin) filament.
The b-AReligand complex acts via G proteins to stimulate
the adenylate cyclase catalytic unit to generate cAMP.23,24 In
the cirrhotic rat heart, it has been previously demonstrated that
there are several defects in b-AR-signaling pathways,
including decreased b-AR density, reduced Gs- and Gi-protein
levels, uncoupling of b-AReligand complex from G protein,
and reduced generation of cAMP.25e282.2. Altered membrane biophysical characteristicsIt has also been shown that altered membrane biophysical
characteristics, including decreased fluidity, impair car-
diomyocyte function.4e6,29,30 However, normalization of
fluidity in cardiomyocyte membrane preparations by an
in vitro fluidizing fatty acid analog, A2C, only partially
restored the cAMP-generating ability, suggesting that other
mechanisms play a role in CCM.29,302.3. Endogenous cannabinoidsEndogenous cannabinoids such as anandamide are also
involved in CCM. Ba´tkai et al reported increased circulating
anandamide and expression of CB1 receptors in vascular
endothelial cells of cirrhotic rats and patients with cirrhosis.31
Gaskari et al recently showed that blockade of endocannabi-
noid signaling improved cardiac contractility in cirrhotic rats
both in vitro and in vivo through a CB1-mediated pathway
dependent on Gi protein.32,33 The source of endocannabinoids
appears to be local cardiac overproduction, stimulated bya stress such as tachycardia. Thus, cannabinoids may
contribute to the blunted responsiveness to cardiovascular
stimuli,34 but do not appear to affect baseline contractility.
Increased TNF-a levels, acting via nuclear factor-kappa
Beinducible nitric oxide synthase and p38MAPK-signaling
pathways, play an important role in the pathogenesis of car-
diodepression in cirrhotic mice. TNF-a also suppressed
contractility by increasing oxidative stress and endocannabi-
noid activity.352.4. SRThe major source of cytosolic calcium transients is the SR.
Not only is the flux of intracellular calcium via RyR release
critical for systolic contraction, but also is the reuptake of
calcium by SR Ca2þ-adenosine triphosphatase (called
SERCA-2) significantly affects relaxation rates.36 Phospho-
lamban regulates SERCA-2 by phosphorylation. A previous
study showed that SR mechanisms of calcium release and
reuptake, including RyR2 (the cardiac isoform) and SERCA
protein expression, are intact in the cirrhotic bile duct-ligated
rat heart.37 Thus, to date, calcium-cycling abnormalities in
CCM seem to be limited to the plasma membrane. Accord-
ingly, the primary focus of the current grant proposal is not SR
function.
3. Cardiac function and liver transplantation
When a new liver is implanted, the circulating concentra-
tions of cardiotoxic and vasoactive substances should be
reduced; liver transplantation should, therefore, improve
circulatory changes including the hyperdynamic circulation.
However, some authors have seen a persistent increase in
cardiac output for up to 2 years after liver transplantation,
whereas others have reported an immediate attenuation of the
hyperdynamic circulations.38e40 Therefore, the duration of
hyperdynamic adaptation after liver transplantation is not yet
completely understood. The events occurring during the
intraoperative period should be separated from the immediate
postoperative period and more sustained events. The surgical
procedures significantly stress the heart by causing a sudden
reduction in the cardiac preload, resulting in a decrease in
cardiac output.10 Bleeding and fluid losses during the opera-
tion can further reduce cardiac output. Pulmonary edema has
been observed in a considerable number of patients partly
because of excessive fluid administration.9,10 Another critical
period during the operation is that of reperfusion of the graft
which can, in the occurrence of a postreperfusion syndrome
with cardiac instability, reduce arterial blood pressure and
heart rate.10 However, currently there is no reliable method to
identify patients who are susceptible to developing these
cardiac complications. Therapondos et al reported that the
serum BNP value S 250 pg/mL as a predictor of cardiac
failure in the early post-transplantation period.11 However,
Donovan et al identified only a few patients with left
ventricular dysfunction postoperatively, and all these patients
had normal preoperative cardiac function; therefore, it was not
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Abnormal cardiac responses during transplantation have been
related to a longer postoperative incubation peroid.41 Inter-
estingly, in that study, hyponatremia and indicators of effective
hypovolemia predicted an abnormal cardiac response.
Postoperatively, there is a decrease in cardiac output, heart
rate, pulmonary artery pressure, and an increase in arterial blood
pressure and systemic vascular resistance.39,42 Torregrosa et al
noted a significant improvement in cardiac performance and
a reduction in myocardial mass between 6 and 12 months after
liver transplantation.43 Furthermore, diastolic and systolic
function improved significantly during this period.
More than 80% of patients with end-stage liver disease may
have a cardiovascular and autonomic dysfunction before liver
transplantation.44,45 About two-thirds of the patients with
cirrhosis have an autonomic dysfunction before liver trans-
plantation.41,44,46 The prolonged QT interval reverses in about
half of the patients after liver transplantation, probably as
a result of diminished portosystemic shunting.43,47,48 But in
a minority of the patients, the QT interval may worsen after
liver transplantation.46
In conclusion, liver transplantation is the ultimate treatment for
patients with end-stage liver disease, but perioperatively it exerts
a considerable stress on the cirrhotic heart. However, proper
identification of patient at risk of developing cardiac failure is
difficult. Dobutamine stress test has been applied to identify
patients at risk of developing cardiac complications but at present
we need amore sensitive and specific test to identify those patients
who will develop cardiac failure after liver transplantation. Post-
operatively, cardiac function seems to normalize with improve-
ments in cardiac hypertrophy, diastolic and systolic function, and
QT interval, but more studies on the cardiac effects are needed.
In conclusion, the impaired cardiac contractility in CCM is
different from that seen in alcoholic heart muscle disease
(Table 2). Among the significant pathophysiological mecha-
nisms involved in CCM are reduced b-AR signal transduction
and a defective cardiac electromechanical coupling.48,49 The
cirrhotic heart may be overloaded with a high-output failure,Table 2
Key messages of cirrhotic cardiomyopathies.
Key points
1. Cirrhotic cardiomyopathy presents as impaired contractile responsive-
ness to stress, altered diastolic relaxation.
2. Cirrhotic cardiomyopathy is independent of etiology of cirrhosis and is
different from alcoholic heart muscle disease.
3. Systolic dysfunction can be demasked by physical or pharmacologic
stress.
4. Diastolic dysfunction is detected by echocardiography with the
measurement of reduced E/A ratio.
5. Measurement of QT interval prolongation should be adjusted for heart
rate.
6. Liver transplantation may revert the cardiac dysfunction but surgery and
TIPS insertion may also aggravate this.
7. Cirrhotic cardiomyopathy contributes to hepatorenal syndrome.
8. Treatment is nonspecific and directed toward the left ventricular heart
failure.
TIPS ¼ transjugular intrahepatic portosystemic shunt.while being hyperdynamic with a diastolic dysfunction; strain
may unmask a latent congestive heart failure. No specific
therapy can be recommended for this condition, and
management of patients with CCM should be directed to
prevent congestive heart failure and include conventional
treatment for pulmonary stasis with diuretics. Vasodilators,
such as angiotensin-converting enzyme inhibitors, should not
be used because they present the risk of further aggravation of
the systemic vasodilatory state. Aldosterone antagonists may
have beneficial effects in terms of a reduction in left ventric-
ular dilatation and wall thickness as well as improvement of
diastolic function. Cardiac glycosides do not seem to improve
cardiac contractility in CCM. In addition to their lowering
effect on portal pressure, b-blocker may reduce the hyper-
dynamic load and improve the prolonged QT interval, but
future research should elucidate whether they also improve the
contractile dysfunction, electromechanical abnormalities, and
mortality. In addition, CCM seems to play a role in the
development of HRS. Lastly, we conclude that liver trans-
plantation improves most of the cardiac dysfunction.References
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